Physician profile
Amanda Blanton
NPI 1053398875
$4,013.49
in general payments reported to CMS, 2019-2025
41 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $54.69 · 2022: $426 · 2023: $580 · 2024: $1,321 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,436 · Education: $97.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,435.76 |
| Education | $97.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $781.94 | 2022-2025 | |
| Janssen Biotech, INC. | $384.72 | 2022-2025 | Tremfya, Stelara, Rybrevant |
| E.R. Squibb & Sons, L.L.C. | $293.91 | 2024-2025 | Cobenfy, Opdivo, Opdualag |
| Teva Pharmaceuticals USA, INC. | $233.57 | 2025 | Austedo Xr |
| Celgene Corporation | $230.14 | 2023-2025 | Reblozyl, Pomalyst, Opdivo |
| Novartis Pharmaceuticals Corporation | $153.86 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $147.63 | 2021-2023 | Imbruvica |
| Mirati Therapeutics, INC. | $124.93 | 2023 | Krazati |
| Incyte Corporation | $117.24 | 2024-2025 | Monjuvi, Pemazyre, Jakafi |
| Eisai INC. | $115.91 | 2022-2024 | |
| Ardelyx, INC. | $114.98 | 2025 | Ibsrela |
| Lilly USA, LLC | $106.37 | 2024 | Omvoh, Jaypirca, Verzenio |
| Immunocore Limited | $99.68 | 2024 | Kimmtrak |
| Pfizer INC. | $95.89 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $85.02 | 2022-2025 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $80.29 | 2024-2025 | Rezdiffra, Resmetirom |
| Merck Sharp & Dohme LLC | $79.91 | 2021-2024 | Keytruda |
| Regeneron Healthcare Solutions, INC. | $76.71 | 2022-2025 | Libtayo, Dupixent |
| Otsuka America Pharmaceutical, INC. | $73.82 | 2024-2025 | Rexulti, Abilify Asimtufii |
| Daiichi Sankyo INC. | $69.87 | 2024-2025 | Injectafer |
| Phathom Pharmaceuticals, INC. | $42.36 | 2025 | Voquezna |
| Seagen INC. | $41.33 | 2022-2023 | Tukysa, Adcetris |
| Axsome Therapeutics, INC. | $39.67 | 2025 | Auvelity |
| Ipsen Biopharmaceuticals, INC | $35.91 | 2022 | |
| Astellas Pharma US INC | $33.91 | 2025 | Xtandi, Padcev |
| Array Biopharma INC | $32.11 | 2024-2025 | Lorbrena, Mektovi, Braftovi |
| Takeda Pharmaceuticals U.S.A., INC. | $29.17 | 2022 | |
| Pharmaessentia USA Corporation | $28.62 | 2024 | Besremi |
| Janssen Pharmaceuticals, INC | $28.22 | 2024 | Invega Sustenna, Invega Trinza |
| Organon LLC | $26.70 | 2024 | |
| Adaptive Biotechnologies Corporation | $25.79 | 2025 | Clonoseq |
| Karyopharm Therapeutics INC. | $23.55 | 2025 | Xpovio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.58 | 2023 | Trulance |
| Celltrion USA INC. | $22.43 | 2024 | Zymfentra |
| Jazz Pharmaceuticals INC. | $21.38 | 2023 | |
| Gilead Sciences, INC. | $17.61 | 2025 | |
| Springworks Therapeutics, INC. | $16.96 | 2024 | Ogsiveo |
| Kyowa Kirin, INC. | $15.31 | 2024 | Poteligeo |
| Ferring Pharmaceuticals INC. | $14.77 | 2025 | Rebyota |
| Taiho Oncology, INC. | $14.60 | 2022 | |
| Glaxosmithkline, LLC. | $14.12 | 2025 | Jemperli, Zejula |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Blanton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.